Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2018 02:30 ET | Source: Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB (publ) Bokslutskommuniké för räkenskapsåret 1 maj 2017 – 30 april 2018

FJÄRDE KVARTALET 1 februari 2018 – 30 april 2018 Koncernens nettoomsättning uppgick till 843 tkr (44)1Rörelseresultatet var -28 017 tkr (-37 411)Resultatet efter skatt uppgick till -32 086 tkr...
June 08, 2018 02:30 ET | Source: Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 – April 30, 2018

FOURTH QUARTER February 1, 2018 – April 30, 2018 Consolidated net sales amounted to TSEK 843 compared to TSEK 44 in the fourth quarter the previous yearOperating loss was TSEK 28,017 compared to...
June 05, 2018 02:30 ET | Source: Oasmia Pharmaceutical AB

Resultat från Oasmia Pharmaceuticals fas III-studie har presenterats vid ASCOs årliga möte

Under måndagen amerikansk tid presenterade Oasmia Pharmaceutical AB de uppföljande resultaten från den genomförda fas III-studien med Apealea® för behandling av äggstockscancer. Uppsala,...
June 05, 2018 02:30 ET | Source: Oasmia Pharmaceutical AB

Results from Oasmia Pharmaceutical’s phase III study have been presented at ASCO annual meeting

During Monday Oasmia Pharmaceutical AB presented the follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer. Uppsala, Sweden, June 5, 2018 - The 2018...
May 30, 2018 11:45 ET | Source: Oasmia Pharmaceutical AB

Nexttobe förlänger lån till Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (NASDAQ: OASM) meddelar idag att Nexttobe AB har förlängt sitt lån till bolaget. Det nuvarande lånet från Nexttobe uppgår till 102,4 MSEK exklusive upplupen ränta och förföll...
May 30, 2018 11:45 ET | Source: Oasmia Pharmaceutical AB

Nexttobe Extends Loan to Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company. The...
May 21, 2018 02:30 ET | Source: Oasmia Pharmaceutical AB

Oasmia Pharmaceutical slutför spin-off av veterinära tillgångar till det amerikanska dotterbolaget AdvaVet, Inc.

Oasmia Pharmaceutical AB (Nasdaq: OASM) meddelar idag att man har slutfört överföringen av samtliga veterinärmedicinska tillgångar till det helägda, USA-baserade dotterbolaget AdvaVet, Inc. När...
May 21, 2018 02:30 ET | Source: Oasmia Pharmaceutical AB

Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced the completed transfer of assets into its wholly owned,...
May 17, 2018 02:30 ET | Source: Oasmia Pharmaceutical AB

Resultat från Oasmia Pharmaceuticals fas III-studie presenteras vid ASCOs årliga möte i juni

Oasmia Pharmaceutical AB kommer att presentera uppföljande resultat från den genomförda fas III-studien med Apealea® för behandling av äggstockscancer vid årets ASCO Annual Meeting i Chicago. ...
May 17, 2018 02:30 ET | Source: Oasmia Pharmaceutical AB

Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June

Oasmia Pharmaceutical AB announce that follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer will be presented at the 2018 ASCO Annual Meeting in Chicago. ...